Quarterly ResultMay 15, 2026, 05:08 PM
Sintx Technologies Q1 Net Loss $(2.82)M; Substantial Doubt on Going Concern
AI Summary
Sintx Technologies reported a net loss of $(2.82) million for Q1 2026, an increase from $(2.29) million in Q1 2025, with total revenue slightly up to $0.38 million. The company's cash and cash equivalents significantly decreased to $1.89 million from $4.14 million at year-end 2025, and net cash used in operating activities nearly doubled. Management has concluded that substantial doubt remains regarding the company's ability to continue as a going concern.
Key Highlights
- Net loss increased to $(2.82) million in Q1 2026 from $(2.29) million in Q1 2025.
- Total revenue slightly increased to $0.38 million in Q1 2026 from $0.37 million in Q1 2025.
- Cash and cash equivalents decreased to $1.89 million as of March 31, 2026, from $4.14 million.
- Net cash used in operating activities was $(2.49) million in Q1 2026, up from $(1.30) million.
- Accumulated deficit grew to $(294.9) million as of March 31, 2026.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Received FDA 510(k) clearance for SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025.
- Sold $0.7 million under the ATM agreement through March 31, 2026, with $5.7 million remaining.
Price Impact
More from SINT